Rituximab inhibits Kv1.3 channels in human B lymphoma cells via activation of FcγRIIB receptors
- 29 February 2012
- journal article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1823 (2) , 505-513
Abstract
No abstract availableKeywords
Funding Information
- Department of Health and Human Services
- National Institutes of Health (5R01-DK067110, 5R37-DK037963)
This publication has 49 references indexed in Scilit:
- A critical role for FcgammaRIIB in up-regulation of Fas ligand induced by a microbial polysaccharideClinical and Experimental Immunology, 2011
- CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodiesBlood, 2011
- Radiolabeling of rituximab with 188Re and 99mTc using the tricarbonyl technologyNuclear Medicine and Biology, 2011
- Understanding rituximab function and resistance: implications for tailored therapyFrontiers in Bioscience-Landmark, 2011
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin LymphomaCell, 2010
- FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implicationsNature Reviews Immunology, 2010
- Engineered anti‐CD20 antibodies with enhanced complement‐activating capacity mediate potent anti‐lymphoma activityCancer Science, 2009
- Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response programJournal of Experimental Medicine, 2007
- Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseasesProceedings of the National Academy of Sciences, 2006
- FcγRIIb Modulation of Surface Immunoglobulin-induced Akt Activation in Murine B CellsJournal of Biological Chemistry, 1999